Related Experiment Video
Updated: Jun 20, 2026
Induction and Testing of Hypoxia in Cell Culture
Published on: August 12, 2011
Hypoxia inducible factor-1 alpha and vascular endothelial growth factor in biopsies of small cell lung carcinoma
M Ioannou1, R Papamichali, E Kouvaras
1Department of Pathology, Medical School, University of Thessaly, Mezourlo, Larissa, 41110, Greece.
Abstract:
Neoangiogenesis has been documented in small cell lung carcinoma (SCLC). In addition, antiangiogenic therapies are being tested in clinical trials that involve SCLC. However, study of the underlying mechanisms has been performed almost exclusively in cell lines. In the current study, we immunostained 30 biopsy samples of SCLC with antibodies to hypoxia inducible factor-1 alpha (HIF-1 alpha), vascular endothelial growth factor (VEGF), vascular endothelial growth factor-receptor 1 (VEGF-R1/flt-1) and vascular endothelial growth factor-receptor 2 (VEGF-R1/flk-1). The immunoreactivity was analyzed using a bivariate Spearman correlation test and linear regression analysis. We found significant correlation between HIF-1 alpha nuclear staining and VEGF staining. Moreover HIF-1 alpha+/VEGF+ cases were associated with poor survival. We also found a positive correlation between VEGF and VEGF-R2 expression. We suggest that a HIF-1 alpha/VEGF angiogenic pathway may exist in vivo in SCLC, similar to that in non-SCLC. Our data also suggest a potential VEGF/VEGFR-2 autocrine pathway in SCLC. The inclusion of novel inhibitors to HIF-1 alpha and other factors may optimize antiangiogenic interventions in SCLC.
Insights
A study in small cell lung cancer (SCLC) found that the hypoxia-inducible factor-1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF) pathway is linked to poor survival. Targeting this pathway may improve antiangiogenic therapies for SCLC.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Neoangiogenesis is observed in small cell lung carcinoma (SCLC).
- Antiangiogenic therapies are under investigation for SCLC.
- Previous mechanistic studies relied heavily on cell lines.
Purpose of the Study:
- To investigate the in vivo expression of key angiogenic factors in SCLC biopsy samples.
- To explore the correlation between hypoxia-inducible factor-1 alpha (HIF-1 alpha) and vascular endothelial growth factor (VEGF) in SCLC.
- To identify potential molecular targets for optimizing antiangiogenic interventions in SCLC.
Main Methods:
- Immunostaining of 30 SCLC biopsy samples for HIF-1 alpha, VEGF, VEGF-R1, and VEGF-R2.
- Bivariate Spearman correlation and linear regression analysis of immunoreactivity.
- Correlation analysis between protein expression and patient survival.
Main Results:
- Significant correlation found between HIF-1 alpha nuclear staining and VEGF staining.
- Cases with high HIF-1 alpha and VEGF expression were associated with poorer survival.
- Positive correlation observed between VEGF and VEGF-R2 expression.
Conclusions:
- A HIF-1 alpha/VEGF angiogenic pathway likely operates in vivo in SCLC.
- A potential VEGF/VEGFR-2 autocrine pathway may exist in SCLC.
- Inhibitors targeting HIF-1 alpha could enhance antiangiogenic therapies for SCLC.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
02:17The Tumor Microenvironment